Patents by Inventor Shaun D. Abbott

Shaun D. Abbott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives
    Patent number: 8258295
    Abstract: We describe compounds of the following general formula (I): wherein X is fluorine or chlorine; Y is oxygen, sulfur, or an amino group; R is an amino, hydroxyl, sulfonamide, or carboxamide group or an N-monomethyl or N-dimethyl analog thereof; m is an integer from 2 to 6, and n is an integer from 0 to 2. The compounds may be used for treating certain cancers and autoimmune diseases.
    Type: Grant
    Filed: April 25, 2008
    Date of Patent: September 4, 2012
    Assignee: Prometic Biosciences Inc.
    Inventors: Boulos Zacharie, Christopher Penney, Lyne Gagnon, Brigitte Grouix, Lilianne Geerts, Shaun D. Abbott
  • Triazine Derivatives, Compositions Containing Such Derivatives, and Methods of Treatment of Cancer and Autoimmune Diseases Using Such Derivatives
    Publication number: 20100129350
    Abstract: We describe compounds of the following general formula (I): wherein X is fluorine or chlorine; Y is oxygen, sulfur, or an amino group; R is an amino, hydroxyl, sulfonamide, or carboxamide group or an N-monomethyl or N-dimethyl analog thereof; m is an integer from 2 to 6, and n is an integer from 0 to 2. The compounds may be used for treating certain cancers and autoimmune diseases.
    Type: Application
    Filed: April 25, 2008
    Publication date: May 27, 2010
    Applicant: PROMETIC BIOSCIENCES INC.
    Inventors: Boulos Zacharie, Christopher Penney, Lyne Gagnon, Brigitte Grouix, Lilianne Geerts, Shaun D. Abbott
  • Triazine dimers for the treatment of autoimmune diseases
    Patent number: 7683061
    Abstract: Compounds containing two mono- or disubstituted triazine rings covalently linked by an organic linker, but not linked directly to each other, may be used to treat autoimmune diseases. Autoimmune diseases which are amenable to treatment with compounds of this invention include rheumatoid arthritis, systemic lupus erythematosus (SLE), idiopathic (immune) thrombocytopenia (ITP), glomerulonephritis and vasculitis. The present invention also relates to reducing drug toxicity which often accompanies traditional therapies for autoimmune diseases. The compounds may also be used to bind antibody in vitro or ex vivo.
    Type: Grant
    Filed: November 22, 2004
    Date of Patent: March 23, 2010
    Assignee: ProMetic BioSciences Inc.
    Inventors: Christopher Penney, Boulos Zacharie, Shaun D. Abbott, Jean-François Bienvenu, Alan D. Cameron, Jean-Simon Duceppe, Abdallah Ezzitouni, Daniel Fortin, Karine Houde, Nancie Moreau, Nicole Wilb, Brigitte Grouix, Lyne Gagnon
  • 2,4,6-triamino-s-triazine-based compounds which bind to the tail (fc) portion of immunoglobulins and their use
    Publication number: 20090068169
    Abstract: The present invention describes new compounds which are useful for binding to the tail or Fc portion of immunoglobulins and so have utility in those applications which require the non-covalent binding interaction of a molecule with the Fc portion of immunoglobulins. Such applications include the detection and purification of immunoglobulins as well as the treatment of certain autoimmune diseases.
    Type: Application
    Filed: September 2, 2005
    Publication date: March 12, 2009
    Inventors: Christopher Penney, Boulos Zacharie, Shaun D. Abbott, Jean-Francois Bienvenu, Alan D. Cameron, Jean-Simon Duceppe, Abdallah Ezzitouni, Daniel Fortin, Karine Houde, Nancie Moreau, Nicole Wilb, Brigitte Grouix, Lyne Gagnon